GLPG Short Information, Galapagos NV

Twenty Trading Day Totals
Total Shorted Volume	982,237
Total Actual Volume	4,476,037

Averages
Average Short Volume	49,112
Average Short Percentage	68.91%

Is there a GLPG Short Squeeze or Breakout about to happen?

See the GLPG Short Analysis for free Sign up or Login

Stock Date	Open Price	Close Price	High	Low	Total Volume	Short Volume	Short Percentage
2021-10-21	51.32	51.94	52.03	51.15	179,481	33,784	67.2439
2021-10-20	51.99	51.61	52.14	51.55	134,354	47,644	84.9012
2021-10-19	51.48	52.4	52.71	51.45	94,603	11,870	59.4481
2021-10-18	51.92	51.65	52.03	51.38	181,046	56,111	82.8708
2021-10-14	54.07	54.21	55.06	53.92	249,237	43,018	56.4941
2021-10-13	52.38	54.09	54.43	52.34	435,064	127,558	66.6172
2021-10-12	50.04	50.09	50.32	49.401	201,542	27,326	50.6253
2021-10-11	49.96	49.71	50.36	49.5	161,333	16,405	43.6326
2021-10-07	48.81	50.24	51.14	48.66	262,921	74,290	72.2342
2021-10-06	49.5	49.47	49.96	49.08	331,643	110,658	86.1326
2021-10-05	49.93	50.57	50.805	49.92	364,055	116,291	85.7629
2021-10-04	51.84	51.17	51.86	51	324,057	64,237	80.2230
2021-10-01	52.92	53.59	53.705	52.5	160,448	20,942	56.9215
2021-09-29	52.67	52.17	52.93	52	161,028	21,718	61.6446
2021-09-24	54.02	53.45	54.18	53.3	149,277	24,847	73.2690
2021-09-23	54.16	54.12	54.34	53.9	154,300	20,110	55.9528
2021-09-22	54.04	53.98	54.46	53.905	210,630	80,575	87.9074
2021-09-21	53.51	54.04	54.57	53.51	240,805	42,579	71.5818
2021-09-20	53.94	54.83	55.32	53.94	186,222	20,724	70.9799
2021-09-17	55.57	55.64	55.99	54.85	293,991	21,550	63.7310

Stock Information

Galapagos NV Company Name:

GLPG Stock Symbol:

NASDAQ Market:

Galapagos NV Website:

GLPG Short Information, Galapagos NV

Get GLPG Alerts

News, Short Squeeze, Breakout and More Instantly...

GLPG - Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress

C ontinuing filgotinib 200mg among induction non-respon d ers at w eek 10 resulted in clinical benefits for ulcerative colitis (UC) patients in the long-term extension study (LTE) T reatment with fil...
GLPG - Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn's Disease

1 , 374 patients enrolled into the phase 3 study across 369 global sites Topline data anticipated in H 1 202 3 Galapagos will assume responsibility f or the D IVERSITY study Mechelen, B...
GLPG - GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Mechelen, Belgium ; 17 September 2021 ; 13.15 CET ; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opi...